Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.67 |
| ▸ | NPC1 | O15118 | 6/20 | 0.59 |
| ▸ | RAB9A | P51151 | 6/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.59 |
| ▸ | SCN4A | P35499 | 2/20 | 0.59 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | GMNN | O75496 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22436025 | 0.87 | DYRK1A (0.61) | DYRK1ANPC1RAB9ASMN1; SMN2SCN4A | |
| SCHEMBL9776980 | 0.86 | DYRK1A (0.70) | DYRK1ANPC1RAB9ASMN1; SMN2SCN4A | |
| SCHEMBL22435996 | 0.85 | DYRK1A (0.59) | DYRK1ANPC1RAB9ASMN1; SMN2SCN4A | |
| SCHEMBL2116986 | 0.84 | NPC1 (0.68) | DYRK1ANPC1RAB9ASMN1; SMN2SCN4A | |
| SCHEMBL2733120 | 0.84 | NPC1 (0.65) | DYRK1ANPC1RAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL28878452 | 0.83 | DYRK1A (0.67) | DYRK1ANPC1RAB9ASMN1; SMN2SCN4A | |
| SCHEMBL29975006 | 0.83 | DYRK1A (0.67) | DYRK1ANPC1RAB9ASMN1; SMN2SCN4A | |
| SCHEMBL23697876 | 0.83 | DYRK1A (0.57) | DYRK1ANPC1RAB9ASMN1; SMN2SCN4A | |
| SCHEMBL8430889 | 0.83 | DYRK1A (0.70) | DYRK1ANPC1RAB9ASMN1; SMN2SCN4A | |
| SCHEMBL9776965 | 0.82 | DYRK1A (0.65) | DYRK1ANPC1RAB9ASMN1; SMN2SCN4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911369-B2 | Prodrugs of riluzole and their method of use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-02-27 | — | — | US | disclosed |
| US-20230381149-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2023-11-30 | — | — | US | disclosed |
| US-20230381150-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2023-11-30 | — | — | US | disclosed |
| US-20230381149-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2023-11-30 | — | — | US | disclosed |
| US-20230017637-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2023-01-19 | — | — | US | disclosed |
| US-20220396555-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD. (US) | 2022-12-15 | — | — | US | disclosed |
| US-20210236470-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | 2021-08-05 | — | — | US | disclosed |
| US-20210236471-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2021-08-05 | — | — | US | disclosed |
| US-20210228549-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2021-07-29 | — | — | US | disclosed |
| US-11052070-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2021-07-06 | — | — | US | disclosed |
| US-10905681-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20200289475-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2020-09-17 | — | — | US | disclosed |
| US-10639298-B2 | Prodrugs of riluzole and their method of use | BIOHAVEN THERAPEUTICS LTD. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20180036290-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2018-02-08 | — | — | US | disclosed |
| US-20180037557-A1 | PRODRUGS RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2018-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381150-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | DYRK1A 3818/4885NPC1 3564/4885RAB9A 985/4885 |
| US-10905681-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | DYRK1A 3818/4885NPC1 3564/4885RAB9A 985/4885 |
| US-20200289475-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | DYRK1A 3818/4885NPC1 3564/4885RAB9A 985/4885 |
| US-20180036290-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | DYRK1A 3818/4885NPC1 3564/4885RAB9A 985/4885 |
| US-11911369-B2 | Prodrugs of riluzole and their method of use | APEH, UGT1A9, ALDH3A1 | DYRK1A 3437/4885NPC1 3132/4885RAB9A 1164/4885 |
| US-20210236471-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | DYRK1A 3818/4885NPC1 3564/4885RAB9A 985/4885 |
| US-20230017637-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | DYRK1A 3818/4885NPC1 3564/4885RAB9A 985/4885 |
| US-11052070-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | DYRK1A 3818/4885NPC1 3564/4885RAB9A 985/4885 |
| US-20180037557-A1 | PRODRUGS RILUZOLE AND THEIR METHOD OF USE | APEH, CYP2C9, ALDH1A2 | DYRK1A 3736/4885NPC1 3362/4885RAB9A 983/4885 |
| US-10639298-B2 | Prodrugs of riluzole and their method of use | APEH, UGT1A9, ALDH3A1 | DYRK1A 3437/4885NPC1 3132/4885RAB9A 1164/4885 |
| US-20210236470-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | DYRK1A 3437/4885NPC1 3132/4885RAB9A 1164/4885 |
| US-20210228549-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | DYRK1A 3818/4885NPC1 3564/4885RAB9A 985/4885 |
| US-20230381149-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | DYRK1A 3818/4885NPC1 3564/4885RAB9A 985/4885 |
| US-20220396555-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | DYRK1A 3437/4885NPC1 3132/4885RAB9A 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.